Tricol Biomedical
Founded Year
2001Stage
Acquired - II | AcquiredTotal Raised
$12MAbout Tricol Biomedical
Tricol Biomedical, formerly HemCon Medical Technologies, offers acute wound care with products that provide rapid Hemorrhage Control (HemCon) of bleeding, protection of wounds, and promotion of normal healing. Through research, the company has delivered a wide range of proprietary and patent-protected OneStop, HemCon, and m.doc branded products for hemostasis to address the varying needs of patients and their healthcare professionals, military medics, paramedics, first responders, and consumers.
Missing: Tricol Biomedical's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Tricol Biomedical's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Tricol Biomedical
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Tricol Biomedical is included in 1 Expert Collection, including Medical Devices.
Medical Devices
3,088 items
Companies that have been granted at least 1 510(k) by the FDA since 2014. Companies tagged as #FDA510(K)
Tricol Biomedical Patents
Tricol Biomedical has filed 20 patents.
The 3 most popular patent topics include:
- Dosage forms
- Drug delivery devices
- Biomaterials
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
12/28/2018 | 5/30/2023 | Kidney diseases, Polysaccharides, Medical equipment, Diabetes, Nephrology | Grant |
Application Date | 12/28/2018 |
|---|---|
Grant Date | 5/30/2023 |
Title | |
Related Topics | Kidney diseases, Polysaccharides, Medical equipment, Diabetes, Nephrology |
Status | Grant |
Latest Tricol Biomedical News
Jan 6, 2021
01/06/2021 | 02:51pm EST Message : *Required fields NORTHFIELD, Ill., Jan. 6, 2021 /PRNewswire/ -- Medline and Tricol Biomedical, Inc. today announced an exclusive agreement to distribute Hemostatic Control (HemCon) products in North America to acute care, emergency services, and cath lab providers. Severe bleeding accounts for over 35% of pre-hospital deaths and close to 40% of deaths within the first 24 hours of sustaining an injury, according to a 2015 National Trauma Institute estimate . Rapid control of bleeding can be applied across specialties within the continuum of care, from Trauma to Cardiology to Home Health. "Managing blood loss within a healthcare facility can prevent unnecessary deaths in severe cases or improve a patient's care experience during vascular access procedures or routine dialysis treatments," says Mitchel Kenoe, director of product management at Namic, a division of Medline. From traumatic injuries to elective procedures, hemostasis products from Tricol Biomedical are designed to advance the standard of care, with product technologies that rapidly control bleeding even for patients taking oral anticoagulants while providing a barrier to bacterial penetration into the wound. Medline and Tricol's exclusive offering includes: HemCon ChitoPulse – The HemCon ChitoPulse is a clinically differentiated radial hemostatic device that combines air pressure and chitosan technology to quickly and safely control bleeding following transradial catheterizations. HemCon OneStop Vascular – The HemCon OneStop Vascular is a hemostatic dressing designed to rapidly control bleeding following catheterizations for all vascular access sites. ChitoGauze XR2 Pro – The ChitoGauze XR2 Pro is a flexible hemostatic chitosan-coated gauze dressing designed to stop severe bleeding within minutes. ChitoGauze OTC – The ChitoGauze OTC is a hemostatic gauze dressing for temporary use on minor wounds. HemCon ChitoDot – The HemCon ChitoDot is a double-sided hemostatic dressing used for local management of bleeding in patients following hemodialysis. "This distribution agreement combines a best-in-class bleeding control product line from Tricol Biomedical with the depth of service to healthcare providers from Medline. This enables us to achieve our ultimate goal of improving patient care and outcomes by eliminating preventable deaths due to blood loss," says Brian Clare, Ph.D., vice president of business operations at Tricol Biomedical. "Since our inception, we have relied on the very best research and development to build our world-class offering. Medline will expand our reach to healthcare providers across the continuum of care." To learn more about this bleeding control offering from Medline, please visit: https://www.medline.com/pages/who-we-serve/acute-care/ To purchase bleeding control products from Medline, please visit us here . About Medline: Medline is a healthcare company; a manufacturer, distributor and solutions provider focused on improving the overall operating performance of healthcare. Medline works with both the country's largest healthcare systems and independent facilities across the continuum of care to provide the clinical and supply chain resources required for long-term financial viability in delivering high quality care. With the size of one of the country's largest companies and the agility of a family-owned business, Medline is able to invest in its customers for the long-term and rapidly respond with customized solutions. Headquartered in Northfield, Ill., Medline has 27,000+ employees worldwide, a fleet of nearly 1,000 trucks and does business in more than 90 countries. Learn more about Medline at www.medline.com . About Tricol Biomedical, Inc.: Tricol Biomedical Inc. (formerly HemCon Medical Technologies, Inc.), originally founded in 2001 and re-invented in April 2016, develops and markets innovative medical technologies that address wound care from closure to treatment. The company is the proud owner of the HemCon brand product line, designed for medical professionals in hospital, dental and clinical settings, as well as military and civilian first responders, where rapid control of bleeding is of critical importance. Tricol Biomedical is headquartered in Portland, Ore., with additional commercial operations in Ireland and the Czech Republic. For more information, please visit www.tricolbiomedical.com .
Tricol Biomedical Frequently Asked Questions (FAQ)
When was Tricol Biomedical founded?
Tricol Biomedical was founded in 2001.
Where is Tricol Biomedical's headquarters?
Tricol Biomedical's headquarters is located at 720 SW Washington Street, Portland.
What is Tricol Biomedical's latest funding round?
Tricol Biomedical's latest funding round is Acquired - II.
How much did Tricol Biomedical raise?
Tricol Biomedical raised a total of $12M.
Who are the investors of Tricol Biomedical?
Investors of Tricol Biomedical include Tricol International Group, TriStar Wellness Solutions, Camden Partners and Torch Hill Investment Partners.
Who are Tricol Biomedical's competitors?
Competitors of Tricol Biomedical include SynergEyes, Wright Medical Group, Hansen Medical, TrueVision Systems, ClearCount Medical Solutions and 13 more.
Compare Tricol Biomedical to Competitors
TrueVision Systems, dba TrueVisions 3D Surgical, provides digital 3D visualization and guidance for microsurgery. The company has developed an intelligent, real-time, 3D surgical visualization and computer-aided guidance platform. TrueVision combines 3D visualization and guidance software applications focused on improving accuracy, efficiency, and outcomes for both surgeons and patients. The company is developing 3D guidance applications for microsurgery to improve surgical efficiencies and patient outcomes. The Refractive Cataract Toolset is a computer-aided software for astigmatic correction and advanced IOL positioning.
Nephrologix Inc. is a private company that develops, manufactures and markets peritoneal dialysis (PD) systems.
Holochip manufactures adaptive polymer singlet lenses that allow adjustability of focal length without changing the location of the lens. This flexibility aims to provide a compact, rugged and reliable solution for utilizing and manipulating light.
Osteosymbionics is a medical device company. It had developed the Osteosymbionics Patient Specific Cranial Implant.We work very hard to make great implants that help people. Computer tools are effective, but sometimes the eyes and hands of a sculptor are what makes the difference in a complex reconstructive case. The blending of artistry and engineering contributes to our ability to make almost anything that a surgeon needs to help a patient.
Spineworks Medical, Inc. designs and manufactures medical devices for spinal surgery.
Optim designs, develops, manufactures, and markets imaging products and accessories that help professionals in the medical, law enforcement, and industrial markets perform visualization procedures more effectively and efficiently. The ENTity Series for medical and the FreedomView Series for industrial and security markets utilize the company's OptiLux LED lighting technology freeing users from tethered or bulky external devices. Optim owns the trademarks for Optim, ENTity, FreedomView, and OptiLux.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.